Welcome to our dedicated page for Annexon SEC filings (Ticker: ANNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Annexon, Inc. (Nasdaq: ANNX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory documents, including current reports, registration statements and other disclosures related to its complement-focused neuroinflammation platform. Annexon is a clinical-stage biopharmaceutical company developing C1q- and classical complement-targeted therapies for neuroinflammatory and complement-mediated diseases of the body, brain and eye.
Through this page, readers can review Annexon’s Form 8-K current reports, which have included announcements of quarterly financial results, portfolio progress and material changes affecting security holders, such as amendments to common stock purchase warrants. Filings related to public offerings of common stock and pre-funded warrants are made under an effective Form S-3 shelf registration statement, with prospectus supplements detailing the terms of each offering.
As Annexon advances late-stage programs such as tanruprubart in Guillain-Barré syndrome and vonaprument in geographic atrophy, investors may also monitor future annual reports on Form 10-K, quarterly reports on Form 10-Q and additional 8-K filings for updates on clinical development, cash runway and risk factors. Any insider transactions by officers and directors would be reported on Form 4 and can be reviewed alongside these company-level filings.
Stock Titan enhances these SEC documents with AI-powered summaries that highlight key points, explain technical language and help users quickly understand the implications of new filings. Real-time updates from EDGAR ensure that new Annexon filings appear promptly, while AI-generated overviews of 10-K, 10-Q and 8-K reports, as well as insider trading forms, support more efficient analysis of the company’s regulatory and financial disclosures.
Annexon, Inc. reported that Thomas G. Wiggans, its Chairman of the Board, intends to retire from the Board and will not stand for reelection at the company’s 2026 annual meeting of stockholders. His term as director and Chairman will end when his current term expires at that meeting.
Until the conclusion of the 2026 annual meeting, Mr. Wiggans will continue to serve as Chairman of the Board and as a member of the Compensation Committee and the Nominating and Corporate Governance Committee. The company stated that his decision to step down was not due to any disagreement regarding operations, policies, practices, strategy, management, or the Board.
Annexon, Inc. (ANNX) received an updated ownership report from investment firm Redmile Group, LLC, its principal Jeremy C. Green, and fund Redmile Biopharma Investments II, L.P. They report beneficial ownership of 15,427,866 shares of common stock, or 9.9% of the class.
This total includes 10,050,644 existing shares held for Redmile-managed clients and up to 5,377,222 shares issuable from pre-funded warrants, subject to a 9.99% Beneficial Ownership Limitation. RBI II separately reports 7,288,917 shares, or 4.7% of the class, combining directly held shares and warrants within the same cap. The filers certify the holdings are not for the purpose of changing or influencing control of Annexon.
FMR LLC has filed Amendment No. 5 to a Schedule 13G/A reporting its beneficial ownership in Annexon Inc. common stock. As of the event date of 12/31/2025, FMR LLC and related entities report beneficial ownership of 10,222,470.36 shares, representing 7.1% of Annexon’s common stock.
FMR LLC has sole voting power over 10,216,569 shares and sole dispositive power over 10,222,470.36 shares, with no shared voting or dispositive power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Annexon.
BlackRock, Inc. filed an amended ownership report showing it beneficially owns 8,868,755 shares of ANNEXON INC common stock, representing 6.1% of the class as of the event date 12/31/2025. BlackRock reports sole power to vote 8,773,698 shares and sole power to dispose of 8,868,755 shares, with no shared voting or dispositive power.
The filing explains that these holdings are attributed to certain BlackRock business units, and that various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Annexon’s outstanding common shares. BlackRock certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Annexon.
Annexon, Inc. reported that it has updated its corporate investor presentation to reflect certain business and strategic updates. The revised presentation, dated January 14, 2026, may be used in upcoming meetings with analysts and investors, including at the 44th Annual J.P. Morgan Healthcare Conference. It will also be available in the Investors & Media section of the company's website.
The investor presentation is furnished as Exhibit 99.1 under Item 7.01 and is expressly stated as being furnished, not filed, which means it is not subject to certain liability provisions of the securities laws and is not automatically incorporated into other Securities and Exchange Commission documents.
Annexon, Inc. reported that it issued a press release outlining its 2026 strategic priorities and key milestones for its lead programs. The press release, titled “Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026,” focuses on advancing its next-generation targeted immunotherapy platform for neuroinflammatory diseases and highlights multiple planned registrational milestones in 2026. The full details are provided in the press release attached as Exhibit 99.1 to this report.
Annexon, Inc. director reports open-market stock purchase under a Rule 10b5-1 plan. On 12/01/2025, the reporting person bought 4,115 shares of Annexon common stock in a transaction coded as a purchase. The weighted average purchase price was $4.47 per share, with individual trades executed between $4.43 and $4.50.
After this transaction, the director beneficially owned 50,290 shares held directly. The filing notes that the trades were made pursuant to the director’s Rule 10b5-1 trading plan adopted on March 17, 2025, and the director has agreed to provide detailed trade information within the reported price range upon request.
Annexon, Inc. (ANNX) reported insider share purchases by director Muneer A. Satter through affiliated entities. On November 20, 2025, Alerce Medical Technology Partners, L.P. bought 400,000 shares of common stock at a weighted average price of $4.48. On November 21, 2025, Alerce Medical purchased an additional 422,613 shares at a weighted average price of $4.28. After these transactions, Satter is reported as beneficially owning 9,728,637 shares, held indirectly through a revocable trust, other trusts and entities, Satter Medical Technology Partners, L.P., and Alerce Medical, over which he has sole voting and dispositive power, while disclaiming beneficial ownership beyond his pecuniary interest.